Roche Holding AG said a trial of an experimental medicine for Alzheimer’s disease yielded disappointing results, adding to a long list of failures in the effort to find a treatment for the leading cause of dementia.

The study of gantenerumab in people with the early stages of Alzheimer’s was halted after an interim analysis designed to assess whether the drug was working, Basel, Switzerland-based Roche said in a statement today. Shares of MorphoSys AG, Roche’s partner on the drug, fell the most in a decade.

READ FULL ARTICLE Curated publisher From Bloomberg